Cornerstone Planning Group’s Pacira BioSciences PCRX Stock Holding History

Cornerstone Planning Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$461	Hold	18	–	–	﹤0.01%	1717
2026 Q1	$447	Hold	18	–	–	﹤0.01%	1679
2025 Q4	$367	Sell	18 -43	-70%	-$1.02K	﹤0.01%	1577
2025 Q3	$12K	Buy	61 +43	+239%	+$1.06K	﹤0.01%	728
2025 Q2	$406	Hold	18	–	–	﹤0.01%	1358
2025 Q1	$454	Hold	18	–	–	﹤0.01%	1330
2024 Q4	$462	Buy	+18	New	+$316	﹤0.01%	1168

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cornerstone Planning Group's PCRX Position: Q2 2026 in Review

Cornerstone Planning Group held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 18 shares worth $461. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

Cornerstone Planning Group first reported a position in PCRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $12K in Q3 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Cornerstone Planning Group held 18 shares of Pacira BioSciences worth $461 as of Q2 2026.
Cornerstone Planning Group left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1717 holding.
Cornerstone Planning Group first reported a position in Pacira BioSciences in Q4 2024 and has held it in 7 quarters since.
Cornerstone Planning Group's Pacira BioSciences position peaked at $12K in Q3 2025.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.